To date, off-target toxicity is resolved through the administration of targeted immunosuppressive agents, such as tocilizumab (an anti-IL-6-antibody) or steroid therapy, aiming to better regulate cytokine release syndrome (CRS) [171]. Here, IL6 is linked to congenital rubella syndrome.